Nuvalent chases after Nuvation in ROS1 lung cancer New trial data sets up a filing for Nuvalent's new-generation ROS1 inhibitor in NSCLC, although it has an uphill battle to catch rival Nuvation.

#Nuvalent has said it is on course to file for approval of its #ROS1inhibitor zidesamtinib as a #lungcancer treatment, although rival Nuvation Bio has beaten it to market.

pharmaphorum.com/news/nuvalen...